You are here

MSCs in Lung Inflammatory Diseases and COVID-19

Immunomodulation through human mesenchymal stem cell (MSC) therapy represents a clinically relevant treatment approach that allows for allogeneic use and broad application in immune/inflammatory diseases. These include severe pulmonary injury and inflammatory conditions such as acute respiratory distress syndrome (ARDS), which is associated with bacterial and viral infections. Despite a notable lack of preclinical data, MSC therapy has been proposed as a candidate treatment for severe ARDS and the cytokine storm associated with COVID‐19. Now, a new STEM CELLS Translational Medicine review article from the labs of B. Linju Yen (NHRI, Zhunan, Taiwan) and Men‐Luh Yen (NTUH & College of Medicine, Taipei, Taiwan) discusses the mechanistic evidence for MSC therapy in pulmonary immune/inflammatory disorders and surveys ongoing clinical trials, including those for COVID‐19.